Litigation Details for Purdue Pharma L.P. v. Accord Healthcare Inc. (D. Del. 2020)
✉ Email this page to a colleague
Purdue Pharma L.P. v. Accord Healthcare Inc. (D. Del. 2020)
| Docket | ⤷ Subscribe | Date Filed | 2020-10-08 |
| Court | District Court, D. Delaware | Date Terminated | 2023-04-26 |
| Cause | 35:1 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 10,407,434; 6,488,963; 8,808,741; 8,894,987; 8,894,988; 9,073,933; 9,492,389; 9,492,391; 9,492,392; 9,492,393; 9,522,919; 9,763,933; 9,775,808 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Purdue Pharma L.P. v. Accord Healthcare Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Subscribe and ⤷ Subscribe .
Details for Purdue Pharma L.P. v. Accord Healthcare Inc. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2023-04-11 | 118 | Opinion | OxyContin. (DTX-008). 7. United States Patent No. 6,488,963 to McGinity ("McGinity") is prior…of the Mannion '933 patent, claim 3 of the '808 patent, claim 6 of the '886 patent, claims 3 and 11 of…808 patent, and claim 6 of the ' 886 patent. The second group consists of U.S. Patent Nos… ' 933 patent, claim 3 of the ' 808 patent, and claim 6 of the '886 patent. Claim 3 of…Mannion '933 patent at 159:21-22; ' 808 patent at 159:62-63 ; ' 886 patent at 172:30). All | External link to document |
| 2023-04-26 | 126 | Judgment | quot;the ' 933 patent"), and 9,522,919 ("the ' 919 patent") (D .I. 1); … (5) that claim 21 of U.S. Patent No. 9,522,919 is declared to be invalid on the ground… ' 933 patent, the ' 808 patent, the ' 886 patent, the ' 933 patent, and the '…quot;) infringed U.S . Patent Nos. 9,763 ,933 ("the Mannion ' 933 patent"), 9,775 ,808 (… ("the ' 808 patent"), 9,763 ,886 ("the ' 886 patent"), 9,073 ,933 (" | External link to document |
| 2023-04-26 | 127 | Patent/Trademark Report to Commissioner of Patents | B2; 9,763,886 B2; 9,073,933 B2; 9,522,919 B2; 10,407,434 B2. (Attachments: # 1 Final Judgment)(nms) (Entered… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,763,933 B2; …2020 26 April 2023 1:20-cv-01362 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-03-11 | 14 | Counterclaim AND Answer to Complaint | the ‘886 patent”); 9,073,933 (“the ’933 patent”); 9,522,919 (“the ’919 patent”); and 10,407,434 (“the ’…RELIEF (PATENT INFRINGEMENT OF U.S. PATENT NO. 10,407,434) 74. Purdue and…, 2019, the USPTO issued U.S. Patent No. 10,407,434 (“the ‘434 patent), entitled “PROCESS FOR PREPARING…Mannion ‘933 patent, the ‘808 patent, the ‘886 patent, the ‘933 patent, the ‘919 patent, and the ‘434…United States Patent Nos. 9,763,933 (“the Mannion ’933 patent”); 9,775,808 (“the ’808 patent”); 9,763,886 | External link to document |
| 2020-10-08 | 4 | Patent/Trademark Report to Commissioner of Patents | ; 9,775,808 B2 ; 9,763,886 B2 ; 9,073,933 B2 ; 9,522,919 B2. (kmd) (Entered: 10/08/2020) 8 October… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,763,933 B2 ;…2020 26 April 2023 1:20-cv-01362 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-08-31 | 43 | Stipulation-General (See Motion List for Stipulation to Extend Time) | terms of U.S. Patent Nos. 8,808,741 (the “’741 patent”), 8,894,987 (the “’987 patent”), and 8,894,988…infringement of U.S. Patent Nos. 9,763,933 (“the Mannion ’933 patent”); 9,775,808 (the “’808 patent”); 9,763,886…9,763,886 (the “’886 patent”); 9,073,933 (the “’933 patent”); 9,522,919 (the “’919 patent”) and 10,407,434 …terms of U.S. Patent Nos. 9,492,392 (the “’392 patent”) and 9,492,393 (the “’393 patent”) directed to…terms of U.S. Patent Nos. 9,492,389 (“the ’389 patent”), and 9,492,391 (“the ’391 patent”) directed to | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
